Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Key Takeaways Sasanlimab combined with BCG improved event-free survival in high-risk NMIBC patients, particularly those with CIS and T1 tumors. Subgroup analyses showed EFS benefits across different ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

Key Takeaways UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of ...

In 2025, cytoreductive nephrectomy (CN) remains an integral part of the multidisciplinary management of metastatic renal cell carcinoma (mRCC). Rapid advances in systemic therapies—particularly immune ...

At this year’s American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada, the AUA released their new guideline on genitourinary syndrome of menopause in collaboration with the Society ...

Session ID: 2025-06-29:1a96e3213c8fbb3b6e53ba90 Player Element ID: vjs_video_3 ...

Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.

Key Takeaways Nadofaragene firadenovec achieved a 79% complete response rate in CIS patients at three months, with durable responses at six and nine months. Real-world safety data showed mostly ...

Specifically, the bill cuts funding for CDMRP from $1.509 billion in FY2024 to $650 million in FY2025. Prostate and kidney cancer research is currently funded at $110 million and $50 million, ...

Video content above is prompted by the following: Please review different treatment delivery options available for management of NMIBC. It is an exciting time for NMIBC, as several delivery systems ...